3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
50
Triple Negative Breast Neoplasms
41
Carcinoma, Non-Small-Cell Lung
11
Head and Neck Neoplasms
8
Carcinoma, Renal Cell
8
Ovarian Neoplasms
7
Melanoma
6
Carcinoma, Hepatocellular
6
Pancreatic Neoplasms
5
Neoplasms
5
Neoplasm Metastasis
5
Colorectal Neoplasms
5
Carcinoma, Transitional Cell
5
Uterine Cervical Neoplasms
4
Stomach Neoplasms
4
Small Cell Lung Carcinoma
4
Urinary Bladder Neoplasms
3
Sarcoma
3
Prostatic Neoplasms
3
Gastrointestinal Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Merkel Cell
3
Urogenital Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
HER2-positive Breast Cancer
2
Esophageal Neoplasms
2
Vulvar Neoplasms
1
Urologic Neoplasms
1
Interventions
pembrolizumab
2
Interleukin-2
2
Biopsy
2
montanide ISA 51
1
liposomal doxorubicin
1
cemiplimab
1
cc-486
1
brodalumab
1
atezolizumab
1
SUB1 protein, human
1
Radiotherapy, Image-Guided
1
Quality of Life
1
Psychiatric Rehabilitation
1
Poly I-C
1
Patient Reported Outcome Measures
1
Observation
1
Molecular Diagnostic Techniques
1
Mass Screening
1
Injections
1
Immunotherapy
1
Immunohistochemistry
1
IT-101
1
Genetic Profile
1
Floderm topical cream
1
Drug Therapy
1
Camptothecin
1
CALAA-01
1
Biological Therapy
1
Azacitidine
1
2-cyclohexylidenhydrazo-4-phenyl-thiazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
atezolizumab
×
Breast
×
Clear all
NCT04273061
2025-09-22
CAPTIV-8
British Columbia Cancer Agency
Phase 2
Recruiting
200 enrolled